Lantern Pharma Inc (LTRN)

11:25 AM

Is Lantern Pharma Inc. Stock Overbought or Oversold RSI Indicator AnalysisFree Stock Selection with 300% Return - Newser

11:25 AM

11:18 AM

Why Lantern Pharma Inc. stock attracts strong analyst attentionFree Investment Community - Newser

11:18 AM

07:38 AM

Intrinsic Value of Lantern Pharma Inc. Stock: Is It Undervalued or OvervaluedFree Discussion Group - Newser

07:38 AM

06:01 AM

How Resilient Is Lantern Pharma Inc. Stock During Economic DownturnsHigh Potential Safe Trades - Newser

06:01 AM

Jul 26, 2025

Lantern Pharma secures EU patent for AI-driven cancer drug LP-284 - MSN

Jul 26, 2025

Jul 25, 2025

Published on: 2025-07-26 01:13:11 - PrintWeekIndia

Jul 25, 2025

Jul 25, 2025

What analysts say about Lantern Pharma Inc. stockRapid growth opportunities - PrintWeekIndia

Jul 25, 2025

Jul 25, 2025

Lantern Pharma Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Bellingham Herald

Jul 25, 2025

Jul 25, 2025

Is Lantern Pharma Inc. a good long term investmentFree Stock Market Real-Time Monitoring - Autocar Professional

Jul 25, 2025

Jul 25, 2025

Will Lantern Pharma Inc. stock benefit from interest rate changesExceptional gains - jammulinksnews.com

Jul 25, 2025

Jul 24, 2025

How Lantern Pharma Inc. stock performs during market volatilityBalanced Risk Reward Portfolio - Newser

Jul 24, 2025

Jul 24, 2025

Why Lantern Pharma Inc. stock is on top investor watchlistsOverwhelming financial success - jammulinksnews.com

Jul 24, 2025

Jul 24, 2025

Lantern Pharma Inc. Stock Analysis and ForecastBreakthrough stock performance - Autocar Professional

Jul 24, 2025

Jul 23, 2025

What drives Lantern Pharma Inc. stock priceTremendous gains - Autocar Professional

Jul 23, 2025

Jul 23, 2025

Lantern Pharma (NASDAQ: LTRN) Reports First Complete Response in Phase 1 LP-284 Trial for Aggressive DLBCL - Barchart.com

Jul 23, 2025

Jul 23, 2025

Lantern Pharma reports complete response in aggressive lymphoma patient - Investing.com Australia

Jul 23, 2025

Jul 23, 2025

Lantern Pharma reports complete response in aggressive lymphoma patient By Investing.com - Investing.com Nigeria

Jul 23, 2025

Jul 23, 2025

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial - Business Wire

Jul 23, 2025

Jul 22, 2025

Lantern Pharma (NASDAQ: LTRN) Secures EU Patent For AI-Designed Cancer Drug LP-284 - Barchart.com

Jul 22, 2025

Jul 22, 2025

Lantern Pharma (NASDAQ: LTRN) Secures EU Patent for AI-Designed Cancer Drug LP-284 - The Globe and Mail

Jul 22, 2025

Jul 21, 2025

Lantern Pharma (LTRN) Secures EU Patent for Cancer Drug LP-284 - GuruFocus

Jul 21, 2025

Jul 21, 2025

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy - BioSpace

Jul 21, 2025

Jul 21, 2025

Lantern Pharma (LTRN) Gains Patent Approval for Key Drug in Euro - GuruFocus

Jul 21, 2025

Jul 17, 2025

Lantern Pharma Unveils AI Module for Predicting Cancer Treatment Efficacy - AInvest

Jul 17, 2025